Corcept Therapeutics Announces Second Quarter 2018 Financial Results and Stock Repurchase Program; Provides Clinical Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. ACN
4. IBM
5. DPZ
6. PRIM
7. META
8. IMNN
9. NAVN

Go back to Corcept Therapeutics Announces Second Quarter 2018 Financial Results and Stock Repurchase Program; Provides Clinical Update

Corcept Therapeutics (CORT) Misses Q2 EPS by 4c; Lowers Outlook, $100M Stock Buyback

August 9, 2018 4:25 PM EDT

Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.20, $0.04 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $62.3 million versus the consensus estimate of $68.5 million.

GUIDANCE:

Corcept Therapeutics sees FY2018 revenue of $250-270 million, versus prior of $275-$300... More